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Executive Summary 
Diabetes and cardiovascular disease have always been a topic of interest.  These two 
diseases have major known risk factors affecting the lives of these patients.  Being enrolled in 
the MSN-Nurse Education program, it is important to understand these two diseases and the 
known risk factors to provide proper education to patients with type 2 diabetes while reducing 
the risk of a cardiovascular event.  Cardiovascular disease has been known to be the leading 
cause of mortality in patients with type 2 diabetes.  With diabetes on the rise in the United States, 
it is important to assess changes in these patients to decrease the risk of developing 
cardiovascular disease or a major cardiovascular event such as a myocardial infarction, stroke, or 
death.   The PICOT question addressed in the project is: In patients with type 2 diabetes (P), how 
do diet and exercise (I) compared to lipid lowering agents (C) affect cardiovascular disease (O) 
at a 3-month evaluation (T)?  This is an important topic to address and examine closer since 
many Americans are diagnosed with type 2 diabetes.  If able to address healthy alternatives to 
patients to reduce the risks of major cardiovascular events such as a myocardial infarction or 
stroke, it could potentially save many lives.  As a nurse educator, it is important to provide 
patients with the education they need on proper diet and exercise to make sure they understand 
their disease process and how type 2 diabetes can lead to many cardiovascular issues if they do 
not take care of their health.  If patients will follow a proper diet and exercise, they can decrease 
their risk factors and decrease the cholesterol levels without the need for medications.     
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Living Healthy with Type 2 Diabetes 
Rationale for the Project 
In the United States, there is an increase of individuals with type 2 diabetes affecting 
more than 100 million people.  Patients with type 2 diabetes have a greater risk for developing 
cardiovascular disease.  In patients, over the age of 65, with diabetes, 68% of those individuals 
will die from a cardiovascular event (2015).  There are many contributing factors for developing 
cardiovascular disease however, diet, obesity, lack of physical activity, and cholesterol levels are 
major factors to assess in patients (Martín-Timón et al., 2014).  This is a growing problem 
especially in the United States as more patients are becoming obese and less active.  The 
American Heart Association and American Diabetes Association come together as organizations 
to create guidelines for patients and providers to decrease the risk of cardiovascular disease in 
patients with type 2 diabetes (Croke, 2016).  When taking care of patients that have come to the 
hospital due to a heart attack or a stroke from poorly controlled diabetes, education is important 
to prevent another cardiovascular event.  Nurses need to be educated and updated on the 
guidelines that American Heart Association and American Diabetes Association provides.  The 
role of a nurse educator is important in patients with diabetes who are at risk for cardiovascular 
disease.  In an education setting, nurse educators are the ones providing education to future 
nurses.  Helping them understand the disease process and how it affects the body is critical for 
when they become nurses and care for the increasing patient population who have diabetes.  It is 
also important for the students to understand cardiovascular disease and how it interacts with 
diabetes and affects the arteries in the body.  Not only are nurse educators important in the 
education setting, but they are also vital in the community.  When a patient is newly diagnosed 
with diabetes, there is a lifestyle change that needs to take place.  Providing the patient with 
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appropriate educational classes and materials can help them control the disease and possibly 
reduce the risk factors of a future cardiovascular event.  Often, patients are diagnosed with 
diabetes from their primary care physician.  The patient is normally encouraged to try diet, 
exercise, and weight loss to see if they can control the diabetes.  When the patient returns for 
follow up, if they have unsuccessfully been able to maintain blood sugars with diet, exercise, and 
weight loss, the primary care will typically start the patient on a diabetic medication.  Patients 
then return to their everyday lives and may not fully understand the importance of maintaining 
proper blood sugars.  The patients and families need to realize that it is a lifestyle adjustment.   
As nurse educators, we need to be involved in community health events to help bring 
awareness of diabetes and cardiovascular disease since many people are affected daily.  
Promoting awareness to the physicians and their staff can play a major role in the care of these 
patients.  Providing patients with a diet regimen and helping them stay on the program can help 
prevent worsening of the disease.  Patients need to have routine cholesterol screenings performed 
since that puts them at a higher risk for an event.  Understanding the significance of cholesterol 
levels in each patient and providing the appropriate medications could save a patient’s life.  If a 
patient has been maintaining his or her diabetes but has poorly controlled cholesterol levels, the 
patient is at a high risk for specific cardiovascular event such as a myocardial infarction or 
stroke.  If a patient can follow an appropriate lifestyle, decrease risk factor modifications, and 
take their medications, they will greatly reduce the risk of developing cardiovascular disease.  
Overall, nurse educators can be a vital source of information to not only the patients, but also the 
physicians in detecting the patients who are at risk for cardiovascular disease or major 
cardiovascular events.  
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Literature Synthesis. 
Patients who have diabetes are at a higher risk for developing cardiovascular disease. 
They are also at a higher risk for death when compared to the general population.  A cohort study 
in Sweden looked at 271,174 patients with type 2 diabetes and looked at 5 risk factors: elevated 
hemoglobin A1c levels, elevated low-density lipoprotein cholesterol levels, albuminuria, 
smoking, and elevated blood pressures.  Participants were randomly selected from the Swedish 
National Diabetic Registry.  The goal of the study was to assess the participants to see if they 
were at greater risk of death or a cardiovascular event based on the number of risk factors and if 
they were in appropriate range when compared to the control groups.  The participants were 
followed for a median of 5.7 years.  At the conclusion of the study, the participants who were 
type 2 diabetic and had risk factors but were all in range when compared to the control group had 
no excess risk of death, myocardial infarction, or stroke when compared to the general 
population.  However, the participants who were type 2 diabetic and had hemoglobin A1c levels 
out of the target range were at greater risk for stroke and myocardial infarction.  Smoking was 
also a major contributor to death in this patient population (Rawshani et al., 2018).   
 Diabetes continues to be on the rise worldwide and cardiovascular disease is a major 
cause of mortality in this patient population.  A literature review assessed patient with type 2 
diabetes to look at the prevalence rate of cardiovascular disease based on sex, age, duration of 
diabetes, body mass index, country.  57 articles were analyzed in the review and included 
multiple countries.  Overall, cardiovascular disease was prevalent in 32.2% of the patients with 
type 2 diabetes and accounts for 50.3% of the deaths in patients with type 2 diabetes (Einarson et 
al., 2018).  One of the key points from the study is understanding the importance of screening for 
cardiovascular disease in patients with type 2 diabetes.  Early prevention screening can decrease 
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the risk of death or a significant cardiovascular event in these patients.  Coronary artery calcium 
assessments have been shown to help diagnose those patients with type 2 diabetes who are at 
greater risk for cardiovascular disease.  Once the patients have completed the test, they can take 
appropriate measures such as diet, exercise, or medications once assessed by a physician.  The 
study does not particularly show any interventions, but it does bring awareness to the growing 
population of patients that are being diagnosed with type 2 diabetes and the prevalence of them 
having a greater risk for developing cardiovascular disease or a major cardiovascular event such 
a stroke, myocardial infarction, or even death.    
The Journal of American Cardiology published a clinical review that discussed 
prevention of cardiovascular disease in patients with diabetes mellitus.  The study was divided 
between the different risk factors: lifestyle, exercise, nutrition, and cholesterol management. 
Three trials were examined in the review on the effects of exercise in patients with type 2 
diabetes: Look-AHEAD, Steno-2 study, and Diabetes Prevention Project.  These studies looked 
at the effects of different lifestyle changes such as weight loss, physical activity, and diet. 
Although there was no direct correlation that that exercise decreases the risk of cardiovascular 
disease in patients with type 2 diabetes, it did show combinations of aerobic and resistance 
training did lower the hemoglobin A1C levels which gave better glycemic control which helps 
decrease the risk of cardiovascular disease.  The current guidelines to reduce the risk of 
cardiovascular disease in patients with type 2 diabetes regarding physical activity is a moderate 
intensity workout for 150 mins or greater per week.  Nutrition is important when it comes to 
assessing these patients.  Counseling patients on the importance of following a proper diet can 
reduce the risk of cardiovascular disease.  Lipid management is evaluated in the review as a 
major risk reduction for cardiovascular disease.  The current guidelines state that patients with 
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diabetes and have cardiovascular disease risk factors need to be on a high intensity statin.  The 
clinical review assessed a meta-analysis which included over 18,000 participants with diabetes 
from 14 randomized trials using statin therapy.  After the mean of 4.3 years there was a 9% 
proportional reduction in mortality and 13% mortality reduction in vascular mortality.  Overall, 
the clinical review demonstrated that diet, exercise, and lipid management did reduce the risk of 
cardiovascular disease (Newman et al., 2017).   
Another clinical review assessed the effectiveness of statin therapy in diabetic patients to 
reduce the risk for cardiovascular disease.  The Cholesterol Treatment Trialists’ Collaboration 
conducted a meta-analysis in a randomized control trial with statin therapy with 1000 patients.  
They were required to take the statin therapy for 2 years for data.  The study showed that 
lowering the LDL by 2 mmol/L with the effective statin therapy can decrease the risk of a 
vascular event in 10% of the participants that were high risk for cardiovascular disease and 5% in 
the low- risk population (Collins et al., 2016).  Newer classes of cholesterol medications are now 
on the market.  Current research and data collections are being examined to determine if there is 
a cardiovascular reduction using the newer class of statin therapy in addition to a high intensity 
statin.  Natural supplements have sparked an interest in many people to reduce cholesterol levels 
and help control blood glucose.  An updated systematic review was studied on the use of 
cinnamon and patients with type 2 diabetes.  The results showed that patients who consumed 
cinnamon on a regular basis over the 4-to-18-week evaluation time had a significant reduction in 
the fasting plasma glucose levels, total cholesterol levels, low density lipoproteins (LDL), 
triglyceride levels, and an increase in the high- density lipoprotein levels.  No significant changes 
were noticed on the hemoglobin A1c levels.  The study provides supportive data for patients who 
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want to add cinnamon supplements to their daily regimen to help reduce blood sugar and 
cholesterol levels.      
 A systematic review of meta-analysis and randomized control trials was conducted using 
the Mediterranean diet compared to controlled diets in patients with type 2 diabetes.  The 
Mediterranean diet is a plant-based diet which helps lower cholesterol levels.  At the conclusion 
of the systematic review, the Mediterranean diet was effective in lowering the risks of 
cardiovascular disease and helped manage glycemic control.  The review included 8 meta-
analysis and 5 randomized control trials that met criteria.  Five of the meta-analysis assessed 
cardiovascular risk factors.  The studies in the review assessed the Mediterranean diets and 
compared it to low fat diets, assessed the reduction in cholesterol levels, and the overall effect on 
body weight.  At the end of the review, the Mediterranean diet did show to have better glycemic 
control and reduction of cardiovascular risk factors when compared to the control diet which 
focused on low fats.  The Mediterranean diet was proven to be the best option for type 2 
diabetics (Esposito et al., 2015).  Another study was published regarding the Mediterranean diet. 
The study was originally a randomized trial in Spain involving 7,447 participants but later had a 
protocol deviation due to not all participants being truly randomized.  The study involved 
patients with type 2 diabetes who were at risk for cardiovascular disease.  There were three diets 
implemented in the trial: Mediterranean diet supplemented with extra virgin olive oil, 
Mediterranean diet supplemented with mixed nuts, and a control diet which was a reduced fat 
diet. The end results of the study showed the patient population who were at high risk for 
cardiovascular disease had a lower risk of major cardiovascular events on the Mediterranean diet 
supplemented with extra virgin olive and mixed nuts compared to the low-fat control diet 
(Estruch et al., 2018).   
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 Not only is diet and cholesterol management important for decreasing the risk of 
cardiovascular disease, but lifestyle changes also need to be assessed.  A meta-analysis examined 
patients with type 2 diabetes to assess lifestyle changes such as diet, exercise, and education to 
see if there is an impact on the clinical markers of cardiovascular disease.  16 randomized control 
trial studies were included in the meta- analysis.  Each study looked at diabetes education, 
supervised exercise programs, and physical activity.  The study found that there was 
improvement with specific lifestyle interventions such as body mass index, hemoglobin A1c, 
systolic blood pressure, and diastolic blood pressure which are associated with the cardiovascular 
risk factors.  All 16 studies included in the meta-analysis had a decrease in the hemoglobin A1c 
levels (Chen et al., 2014).  Other articles were reviewed that supported how a proper diet and 
exercise can affect the risk factors of cardiovascular disease in patients with type 2 diabetes. 
Other studies reviewed looked the effects of cholesterol levels in this patient population. There is 
an important aspect with monitoring the cholesterol levels to reduce major cardiovascular events 
in this patient population. If patients can decrease the cholesterol levels with the diet and exercise 
plan, these patients may greatly benefit if they follow it as prescribed. There are some situations 
where patients can follow a special diet and exercise regularly, but they still may need 
medications to help reduce a major cardiovascular event due to their genetic make-up.  When 
patients can understand the process of diabetes and how it interacts with cardiovascular disease, 
they will soon realize how important exercise is and how it impacts their lives to decrease the 
risk of cardiovascular disease.  Helping these patients maintain a healthy lifestyle with diet and 
exercise could potentially save their lives from a heart attack, stroke, or death.       
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Project Stakeholders 
 Healthcare providers want to provide the best and safest treatment to your patients that 
result in positive outcomes.  Safety is number one when it comes to implementing a change in a 
practice setting.  We do not want to implement a change that can have a negative impact on the 
patient.  The stakeholder such as the CEO, physicians, nurses, and educators need to understand 
the change that will take place and why this change will make a positive outcome on patients.  It 
is key to make sure if they agree to accept the project in their clinical practice setting, that the 
appropriate staff is available to support the project.  Nilsen et al. discusses characteristics related 
to successful changes.  For successful changes, the staff needs to influence the change, prepare 
for the change, and value the change.  All three of these characteristics can relate to the 
stakeholders for positive outcomes (Nilsen et al., 2020).  The patients are also the stakeholders at 
risk.  Some patients may be hesitant to agree to a study because they are not sure of the 
unknown.  Providing proper education to the patients is important so they know that you are not 
there to produce any harm to them but rather want a positive outcome for them in 3 months. 
There are many patients that will say that they have had negative side effects when taking a 
statin medication.  If there is an alternative such as proper diet and exercise to decrease the risk 
of cardiovascular disease, many patients will want to trial that option instead of taking a 
medication.  Franklin et al., performed a recent study relating to person- centered goal setting.  It 
emphasized the importance of including the patient and healthcare provider to determine the 
patient’s goal by working together to achieve a desired outcome (Franklin et al.).  This is 
important with the patient population because we want to work closely with them to decrease 
any major cardiovascular event.  I do understand from working directly with patients that have 
diabetes, they are already at an increased risk for cardiovascular disease, and some will need the 
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additional therapy of cholesterol management and proper diet and exercise to reduce a major 
cardiovascular event.  However, this change is to examine the effectiveness of diet and exercise 
in patients with type 2 diabetes who do not have a history of a major cardiovascular event such 
as acute myocardial infarction or stroke.  
Implementation Plan  
An Internal Medicine Clinic is the anticipated site for implementing the change.  The data 
needed to warrant a change is to collect a select group of patients that are diagnosed with type 2 
diabetes which are at an increased risk for cardiovascular disease.  It is important to select 
patients that have not had a previous myocardial infarction or stroke.  An updated medication list 
needs to be collected.  Patients currently taking statins for cholesterol need to be placed in a 
specific category since part of the assessment is to assess how lipid management can affects 
cardiovascular disease.  The patients are the stakeholders at risk.  Interprofessional collaboration 
plays an important role in the process for making an effective change for the patient.  Key 
professionals involved in the collaboration include the internist, cardiologist, diabetic educator, 
nurses, and a research team.  The internist is the one who manages the patient’s diabetes on a 
regular basis and adjusts his or her medications as needed.  The cardiologist will provide the 
knowledge and understanding of how diabetes affects cardiovascular disease and how to 
decrease the risk of a major cardiovascular event such as a myocardial infarction, stroke, or even 
death.  A diabetic educator will provide education about the disease process of diabetes and 
provide a detailed plan for the patient on proper diet, exercise, and diabetes management to 
decrease the risk for developing cardiovascular disease.  Nurses will provide support and are the 
link of communication.  Nurses will assess the patient’s needs and assure patients that they will 
receive appropriate care while reinforcing the plan for better health.  Nurse researchers provide 
TYPE 2 DIABETES- A CHANGE FOR A BETTER LIFE 14 
current information on type 2 diabetes and cardiovascular disease.  To have access to the clinic, 
the internist will need to agree to participate, and the plan will need to be approved by their Chief 
Executive Officer.  Allies within the organization that can help assist are nurses who work 
directly with the physician.  With any change process there will always be barriers.  Some 
barriers could include the Chief Executive Officer who might be hesitant allowing outsiders into 
the clinic and the need for participation may not be present among the staff in the clinic.  Patients 
may not see the importance of the study and they may not be committed to required follow up 
appointments due to lack of understanding.  Some patients may lack transportation which can 
limit access to the appointments.   
Ways to eliminate or minimize barriers is to be prepared when approaching the company.  
Providing educational information regarding how the patients involved in the change will benefit 
overall from the end results.  Also, providing educational material on diabetes and cardiovascular 
disease to help the staff understand the importance of how these diseases affects patients.  Once 
access has been gained into the clinic space, it is important to assess the resources to be 
successful.  Personnel staff would include the nurses and medical assistants.  The internist will 
oversee the care of the patients.  A nurse practitioner can be utilized for the follow up 
appointments once the initial visit has been performed.  A diabetic educator will play a role in 
educating the patients and will develop a plan for the patients to follow during the 3 months.  
There is not any specific training needed to help carry out the change.  A designated room will 
be needed for the patients to be seen and evaluated.  A phlebotomist is needed to draw baseline 
cholesterol levels and routinely throughout the follow up visits.  There will need to be a contract 
for the designated laboratory to help with the funding to cover the price of the labs.  Consultants 
such a cardiologist, dietician, and a personal trainer will be available if needed during the initial 
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consult and follow up appointments.  The clinic has electronic health records.  Proper electronic 
health record training and obtaining access to chart within the designated health system will need 
to be obtained.  The patient consents and labs can be scanned directly into the patient’s chart and 
follow up notes will be generated in the charting system.  An information technology support 
system will be needed as well to make sure the system is working properly.  Once the change has 
taken place and patients have benefited from the change, the physicians and the nurse clinic staff 
will be responsible to carry out the change moving forward.  When it comes to the planning 
phase, staff engagement is important.  When members of the team are engaged in the process, 
they take ownership in the project and want the results to be successful (Melnyk & Fineout-
Overholt, 2019, p. 205-206).  
Timetable/Flowchart 
The purpose of this project is to examine if appropriate diet and exercise is effective in 
reducing the risks of cardiovascular disease in patients with type 2 diabetes when compared to 
lipid lowering agents.  Due to COVID, I was not able to participate with this project in a facility, 
but I will discuss the plan and an estimated timeline for the project.  Once the project has been 
approved, the first step that needs to be obtained is an acceptance into an internal medicine clinic 
would be the ideal location since the patients included in the study are type 2 diabetics.  The 
patients must have no prior cardiovascular history.  There needs to be a group of patients taking 
prescribed statins and a non- statin therapy group of patients.  The required staff for this project 
include an internal medicine physician, a cardiologist, a diabetic educator, dietician, personal 
trainer/cardiac rehab nurse, office nurse, medical assistant, and nurse research coordinator.  Once 
the staff has been selected, proper education is needed for the staff to educate them on the 
disease process of diabetes and why these patients are at greater risk for developing 
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cardiovascular disease.  The internal medicine physician will oversee the care of the patient, but 
a nurse practitioner can also be the one to oversee the care of the patient for the remaining follow 
up appointments.  In the clinic, there will need to be a designated room of the patients to be seen 
so it will not disrupt the flow of the regular clinic patients.  Electronic health records will be used 
for the project.  Proper training will be required for the electronic health records and the staff will 
need to obtain access to chart within the designated health system.  A phlebotomist will need to 
be available to draw appropriate labs.  A contract will be formed with a local laboratory to run 
the labs once drawn and possible work with the study to help cover the price of the lab for the 
patient.  Consultants such a cardiologist, dietician, and a personal trainer will be available if 
needed during the initial consult and follow up appointments.  Once the patients have been 
selected, the initial visit can be started, and a plan initiated for the patients to follow.  Patients 
will be followed closely and will be required to come in for follow up appointments.  They will 
be required to bring in their diet journal and their exercise log for each appointment.  Each 
month, there will be a team meeting with the staff to discuss the patients progress in detail.  It 
will also be a time to receive feedback from the staff on how well the process is working and if 
anything needs to be revised.  At the end of the 3 months, the information will be recorded one 
the patient has their final appointment.  The patient will complete an evaluation and the outcome 
will be assessed to see if the change was effective.  
Steps: 
• Week 1: Screen and select patients that meet the criteria (Type 2 diabetic, no known 
cardiovascular history, currently taking a statin or not). Schedule a time to consent the 
patient for the study so they can begin the initial workup. 
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• Week 2: Patients will have initial office visit, specific diet and exercise regimen will be 
in place, baseline lipid panel obtained, statin documented.  Patients will be instructed to 
record their food choices and exercise daily.  
• Schedule monthly follow up visits for the next 3 months to assess any cardiovascular 
events such as myocardial infarction, stroke, death. Also, document any changes that 
have taken place since the last office visit (if any changes). Assess their diet- have the 
patient write down their food choices daily and record exercise.  Patients will also have 
lipid panels drawn monthly. 
• Schedule monthly team visits to assess and evaluate to see if a change is needed for the 
next month 
• 3-month visit: During the final visit: draw a final lipid panel to compare to baseline, 
assess for cardiovascular disease or cardiovascular events (myocardial infarction, 
stroke), document if the patient followed the specific diet and exercise regimen. At the 
end of the 3-month follow up visit, the patient will receive their incentive for 
completing the study.  
• Assess the patient outcomes to determine if a diet and exercise plan was effective for 
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Flowchart 
 
*This flowchart is only for patients who are type 2 diabetics, have no history of cardiovascular 
events, and are currently not taking any statin therapy. 
*The compared population will be patients who are type 2 diabetics, no history of cardiovascular 
disease, but are currently taking statin therapy. This population will have their lipid panel drawn 
monthly and will be assessed for any cardiovascular event within the 3- month period. The goal 
is to show the effectiveness of proper diet and exercise to reduce the risk of cardiovascular 




*NO history of cardiovascular disease
*Not currently on any statin therapy
1 Month Follow Up VIsit
Review Diet and Exercise Journal
Consult specialist if needed




Any changes to diet or medications?
2 Month Follow up Visit
Review Diet and Exercise Journal
Consult specialist if needed




Any changes to diet or medications
3 Month/Final Visit
FINAL Evaluation
Review DIet and Exercise Journal
Has the patient had any cardiovacular 
event within the 3 month period?
FInal Lipid Profile Drawn
Vital Signs/Weight
Final medication list collected
Patient is placed on a selected diet such 
as the Mediterranean Diet
Exercise Plan
150 minutes per week of moderate 
intensity aerobic exercise OR
75 minutes of vigorous intensity exercise 
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Data Collection Methods 
The data collection for the benchmark project will be collected from the patients at each 
follow up visit with their exercise and dietary log.  Each patient will have a detailed follow up 
appointment each month for 3 months with a nurse practitioner to assess the progression of the 
patient during the study. The patient will be interviewed during the visit to assess their progress, 
if there has been any hospitalizations, change in medications, or had any cardiac symptoms since 
the last visit.  Cholesterol levels will be drawn on each patient each month and will be collected 
as data.  The providers and the staff involved in the study will have scheduled roundtable 
meetings to discuss how each of the patients are doing and if there is any areas that need 
improvement in the study for the following months.  An important concept to remember during 
the evaluation period is “Patient Centered Quality Care” (Melnyk & Fineout-Overholt, 2019, p. 
218).  Patients need to be included in the evaluation phase.  They are part of the team and should 
be included in the decision making and evaluation phase.  Data needed to evaluate if and how the 
change has impacted the organization would be to have a debriefing session with the physician, 
nurse practitioner, and nursing staff to obtain their thoughts on how the process took place during 
the last 3 months.  Patient testimonies can be a powerful tool for other patients to read in the 
future to gain a better understand on the importance of diabetic management and how to decrease 
the risks of a major cardiovascular event with diet and exercise since they are at a greater risk for 
developing cardiovascular disease.  Education is the key component on how the change affected 
the organization.  If patients received a clear understanding of the importance and purpose of the 
study and are drawn by an incentive at the end of the study, they will be dedicated to completing 
the 3 months with routine monthly follow ups and follow the diet and exercise plan.  The overall 
change for the organization is related to patient care.  If the plan is followed appropriately, 
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patients will have a decreased risk for cardiovascular disease.  Physicians will be able to educate 
their patients on the importance of managing their diabetes to reduce the risk of developing 
cardiovascular disease.  As part of the educational component, providing screenings during 
diabetes awareness and cardiovascular disease awareness months can help bring awareness to the 
patients and community.   
Cost/Benefit Discussion 
It is important to remember cost when developing a plan.  With any change project, there 
are costs are associated with the project.  Since I did not have access in the facility for this 
project, I have assessed the areas that would have a cost attached.  Cost associated with this 
project would include the physician fee, nurse practitioner fee if utilizing for follow up 
appointments, fees to pay for the nursing staff that are being utilized, rent space, laboratory fees 
including the phlebotomist, the price of the lipid panel, and the processing fee, and patient 
incentive fee.  The overall fee for the items listed above will depend on the price set for each 
member of the study.  Once the facility has been chosen, a discussion with the administration 
needs to take place to determine the price to rent an area in their facility.  If able to present the 
purpose of the study to the key stakeholders, they may allow the use of an area without any rent 
fees associated.  It will be important to outline the fees for the physician, nurse practitioner, and 
staff involved.  There are two options that could be effective with the payments.  One option is 
that everyone will receive the payment at the end of the 3 months, or second option is that each 
person receives a payment each month.  This discussion will take place with the office once the 
project has been accepted.  Each patient involved in the project will receive their incentive at the 
end of the 3-month study to make sure they stay active in the study.  The long- term cost will be 
incorporated in the patient’s normal routine follow up appointment if the change is successful.  
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The benefits versus risks/costs analysis will weigh out in the end.  Once the start-up is 
completed, the remaining fees will include payments for rent, physician/nurse practitioner fee, 
staff, and laboratory fees.  However, once the change is successful the additional fees will be 
included in the patient’s follow up fee and no additional fees will be required.  It is difficult to 
determine the amount of money that will be saved with the intervention due to this project being 
a benchmark project.  I would be interested in following up with the project or discussing the 
idea with the facility when they start to allow visitors into the facility.  
Discussion of Results 
 This capstone project was performed as a benchmark project this semester due to COVID 
restriction at the facility that I was interested in using for my patient selection.  It has been a 
great experience even though I was not able to perform the study with actual patients.  My hope 
is that once appropriate patients have been selected for the study that they will benefit greatly 
from a diet and exercise plan to reduce the risk of a major cardiovascular event such as a stoke or 
myocardial infarction.  At this moment, due to the benchmark project, there are no actual results.   
There are many prior research articles that support a low- fat, plant- based diet and following an 
appropriate exercise program that promotes lowering the risk of cardiovascular disease in patient 
with type 2 diabetes.  It will be important to note the patients who have a cardiovascular event 
while enrolled in the study as this will affect the study outcomes.  There are many patients who 
do not respond well to statin therapy due to side effects or other complications.  If able to show 
that a proper diet regimen and exercise plan can be effective for reducing a cardiovascular event, 
then these patients will be motivated to follow the plan especially with they are not able to 
tolerate statins.  There are some patients that require statin therapy due to genetics and a strong 
family history of cardiovascular disease.  The patients may be able to follow the appropriate diet 
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and exercise plan and still require the additional support of taking a high dose statin.  
Sustainability is important with a change project.  Changes can be meaningful to the patient care 
as well as the outcomes.  A change project can impose some challenges to the practice or 
healthcare setting.  With the healthcare setting continuing to change and improve, it is important 
to make sure the data is being updated with the times.  We need to make sure you are utilizing 
the evidence-based practice daily to sustain the change.  It is important to make sure we can 
sustain the change project, so it does not waste the time and financial investment of the study in 
the past (Lennox et al., 2018).  There are some questions to brainstorm when determining 
whether the project will sustain such as to see if there is clear implementations, is there 
commitment from the stakeholders and staff, and financial obligations. Being able to look at the 
questions can help determine if the project will sustain (2017).  Through the evidence- based 
research, it has been shown that proper diet and exercise can reduce the risks of cardiovascular 
disease in patients with type 2 diabetes.  These patients are already at an increased risk for 
developing cardiovascular disease, as a healthcare provider we want to continue to do our best to 
provide optimum care for the patients to help the decrease the risks.  One way to make sure the 
project is sustained is to provide education to the staff and physicians.  Physicians, nurses, and 
the other staff can provide the patients with the proper resources to make sure they are following 
the proper regimen for their diet and exercise plan.  Keeping current on the data is a great way to 
make sure we are giving the patients the best treatment to prevent cardiovascular disease.  It is 
often easy to continue the project when everyone is engaged but often once the project is over, 
people tend to do back to their original ways of treatment.  It is important to make sure the 
research, time, and expenses have not been wasted and the change project can continue in the 
future.    
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Conclusions/Recommendations 
With patients diagnosed with type 2 diabetes, education is significant especially from the 
time of the initial diagnosis.  After extensive research, it has been shown that if a patient will follow 
a Mediterranean diet which is a low-fat, plant-based diet and follows the recommended exercise 
regiment provided to the patient while monitoring their cholesterol levels, they have a potential to 
decrease their risks of cardiovascular disease and major cardiovascular events such as a stroke, 
myocardial infarction, or even death.  Updated research studies would be beneficial on diet and 
exercise for patients with type 2 diabetes and how it affects cardiovascular disease as many studies 
are greater than 5 years.  For this project, 3 months may not be an effective amount of time to fully 
assess the outcomes to determine if these patients will have any cardiovascular events in the future, 
but it is a good starting point to monitor the effects for a major event such as a stroke, myocardial 
infarction, or even death.  Due to COVID restrictions at the facility, this project was performed as 
a benchmark project.  I am interested in implementing this study in the future to see how the 
patients respond with the appropriate diet and exercise plan and monitor the patients to if they have 
any cardiovascular events in the future.  As a nurse, it is essential to provide patients with all the 
resources needed and a plan to promote positive healthy outcomes and wellness with appropriate 
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factors when compared 
to other controlled 
diets.  
 
There is no harm to 
patients if this diet is 
implemented and in fact 
it could help them 
improve their type 2 
diabetes management. 
This study could easily 
be implemented in the 
area of practice since I 
work with cardiac 
patients and many of 
them are diabetics. 
 
Level of evidence: 
Level 1 
 
USPSTF grade: A 
TYPE 2 DIABETES- A CHANGE FOR A BETTER LIFE 39 












oil or nuts.   










from 2013 was 











In 2010- 523 
participants lost 
follow up after 
2 or more years 
IV: 
-Mediterranean 
diet with extra 
virgin olive oil 
-Mediterranean 
diet with nuts 
-Control diet( 

























-Mediterranean diet with 
extra virgin olive oil: End 
point of 96 events 
-Mediterranean diet with 
nuts: End point of 83 
events 
-Control group: end point 
of 109 events 
 
Mediterranean diet extra 
virgin olive oil 
n=2543 
Hazard ratio 0.69 
(95% CI, 0.53-0.91) 
 
Mediterranean diet with 
nuts 
n=2454 
Hazard ratio 0.72 
(95% CI, 0.54-0.95) 
 
 
If site B was also excluded 
with above popluation  
n=5859 
Mediterranean diet with 
extra virgin olive oil: 
Hazard ratio: 0.71 
(95% CI, 0.52 to 0.97) 
Mediterranean diet with 
nuts: 
Hazard ratio: 0.68 







Large sample size 
Close monitoring of 




Exercise was in the 
follow up questionnaire 
but was not examined 
 
There were no risk or 
harm to the patients 
involved in the study. 
All participants signed 
informed consent. 
 
This trial does provides 
good evidence of 
maintaining a 
Mediterranean diet to 
reduce the risk of a 
cardiovascular event in 
patients with type 2 
diabetes. More research 
needs to be completed 
to determine if similar 
outcomes can be 
reproduced in different 
parts of the world. It 
would be a good start in 
my practice to 
encourage patients to 
try tbe Mediterranean 
diet to see if it reduces 
the risk of a 
cardiovascular event. 
 
Level of Evidence: 4 
 
USPSTF grade: B 
 
Einarson, T. 
R., Acs, A., 
Ludwig, C., 




























with T2D-overall 32.2% 
had prevalence of CVD  
 
















AMI: Acute Myocardial Infarction 
BMI: Body Mass Index 
CVD: Cardiovascular disease 
HDL: high density lipoprotein cholesterol levels 
LDL: low density lipoprotein cholesterol levels 
MA: Meta- analysis 
RCT: Random control trial 
SR: Systematic review 
T2D: Type 2 Diabetes 
CCI: Continuous Care Intervention group 
UC: Usual Care group 
MACE: Major Adverse Cardiovascular Events 
 
***Prompts for each column – please do not repeat the headings, just provide the data                                                                                   
















n = 4,289,140 
Rate= 32.2% 
95% CI (30.0 to 34.4) 
 
Male CVD 
n = 241,406 
Rate= 27.7% 




Rate = 27.2% 
95% CI (22.7 to 31.7) 
 
STROBE checklist-risk of 
bias = low 
Studies addressed 80% of 
STROBE checklist 
Mean 80 ± 12% 
 
 
Some articles were 
abstracts 
CVD was not described 
the the same in the 
studies 
 





















*This flowchart is only for patients who are type 2 diabetics, have no history of cardiovascular 
events, and are currently not taking any statin therapy. 
*The compared population will be patients who are type 2 diabetics, no history of cardiovascular 
disease, but are currently taking statin therapy. This population will have their lipid panel drawn 
monthly and will be assessed for any cardiovascular event within the 3- month period. The goal 
is to show the effectiveness of proper diet and exercise to reduce the risk of cardiovascular 





*NO history of cardiovascular disease
*Not currently on any statin therapy
1 Month Follow Up VIsit
Review Diet and Exercise Journal
Consult specialist if needed




Any changes to diet or medications?
2 Month Follow up Visit
Review Diet and Exercise Journal
Consult specialist if needed




Any changes to diet or medications
3 Month/Final Visit
FINAL Evaluation
Review DIet and Exercise Journal
Has the patient had any cardiovacular 
event within the 3 month period?
FInal Lipid Profile Drawn
Vital Signs/Weight
Final medication list collected
Patient is placed on a selected diet such 
as the Mediterranean Diet
Exercise Plan
150 minutes per week of moderate 
intensity aerobic exercise OR
75 minutes of vigorous intensity exercise 
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